These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21476974)

  • 1. Lipoprotein(a): medical treatment options for an elusive molecule.
    Parhofer KG
    Curr Pharm Des; 2011; 17(9):871-6. PubMed ID: 21476974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of and treatment options for increased lipoprotein(a)].
    Zsíros N; Paragh G; Harangi M
    Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latest developments in the treatment of lipoprotein (a).
    Bos S; Yayha R; van Lennep JE
    Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
    Fras Z
    Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options.
    Anagnostis P; Karras S; Lambrinoudaki I; Stevenson JC; Goulis DG
    Int J Clin Pract; 2016 Dec; 70(12):967-977. PubMed ID: 28032426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?
    Santos RD
    Atheroscler Suppl; 2014 Sep; 15(2):19-25. PubMed ID: 25257073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Position of lipoprotein apheresis in present].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Vrablík M; Piťha J; Žák P; Sobotka L
    Vnitr Lek; 2015 Nov; 61(11):958-64. PubMed ID: 26652784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
    Nozue T
    J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
    Khera AV; Qamar A; Reilly MP; Dunbar RL; Rader DJ
    Am J Cardiol; 2015 Jan; 115(2):178-82. PubMed ID: 25432415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels.
    Eraikhuemen N; Lazaridis D; Dutton MT
    Am J Cardiovasc Drugs; 2021 May; 21(3):255-265. PubMed ID: 32929693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R; Rumana U
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How to deal ugly twins, LDL-cholesterol and lipoprotein (a)].
    Piťha J
    Vnitr Lek; 2016; 62(11):903-907. PubMed ID: 28128577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for hyperlipidaemia: an update.
    Florentin M; Kostapanos MS; Kei A; Elisaf MS
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):471-88. PubMed ID: 25356785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biology, pathophysiology and current therapies that affect lipoprotein (a) levels.
    Rawther T; Tabet F
    J Mol Cell Cardiol; 2019 Jun; 131():1-11. PubMed ID: 30986377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H; Burns TL; Hilleman DE
    Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.